<DOC>
	<DOCNO>NCT01548560</DOCNO>
	<brief_summary>This study determine safety dapivirine gel dapvirine film healthy , HIV-uninfected woman age 18-45 year use product 7 daily dos .</brief_summary>
	<brief_title>Assessing Safety Dapivirine Gel Film Formulations</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Age 18 45 year ( inclusive ) screen Able willing provide write informed consent screen take part study . Able willing provide adequate locator information HIVuninfected base test perform study staff screening ( per algorithm Appendices I ) Per participant report , use effective method contraception enrollment ; hormonal method ( except vaginal ring ) use continuously past 30 day ; intrauterine device ( IUD insert least 30 day prior enrollment ) ; female sterilization ; abstinent sexual activity male partner past 30 day ; sexual activity vasectomize partner ; willingness use effective method contraception completion final schedule study visit enrol ( approximately 35 day enrollment ) In general good health determine site clinician For participant old 21 , pap result 12 calendar month prior Enrollment consistent Grade 0 accord Female Genital Grading Table Use Microbicide Studies Addendum 1 DAIDS Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) satisfactory evaluation treatment require nonGrade 0 Pap result per American Society Colposcopy Cervical Pathology ( ASCCP ) guideline per local standard care , 12 calendar month prior Enrollment Note : For participant age 1821 , Grade0 adequately evaluate abnormal Pap smear require American Society Colposcopy Cervical Pathology recommend initiate screen age 21 . Agree sexually abstinent Visit 1 completion Visit 3 Agree use study condom Visits 3 4 ( heterosexually active ) Agree abstain intravaginal product penetration ( include sex toy , exclude tampon ) Visit 3 Willingness undergo studyrelated assessment follow studyrelated procedure At screen enrollment , agree participate research study involve drug , medical device , vaginal product enrol trial Menopause ( define amenorrhea one year without alternative etiology ) Hysterectomy Participant report follow : Known adverse reaction study product ( ever ) Known adverse reaction latex ( ever ) Non therapeutic injection drug use 12 month prior Screening Surgical procedure involve pelvis 90 day prior enrollment ( include dilation curettage evacuation , cryosurgery ; include cervical biopsy evaluation abnormal pap smear ) Participation drug , spermicide and/or microbicide study 30 day prior enrollment anticipated participation investigational drug study next 8 week Pregnancy within 90 day enrollment Currently lactate Use diaphragm , NuvaRingÂ® , spermicide contraception Internal vaginal use device product ( except tampon ) 7 day prior enrollment Urogenital infection suspect infection within 14 day enrollment include : symptomatic candidiasis , trichomonas vaginalis , symptomatic bacterial vaginosis ; cervical infection , include N. gonorrhea , C. trachomatis , mucopurulent cervicitis ; syphilis ; HSV lesion , sore ( Note : seropositive HSV without active lesion exclude ) ; acute pelvic inflammatory disease ; urinary tract infection ; recent exposure partner GC , CT , Trichomonas , syphilis , NGU Antibiotic antifungal therapy ( vaginal systemic ) within 7 day enrollment As determined PI , significant uncontrolled active chronic cardiovascular , renal , liver , hematologic , neurologic , gastrointestinal , psychiatric , endocrine , respiratory , immunologic disorder infectious disease Menses vaginal bleeding time Enrollment visit Has follow laboratory abnormality per Division AIDS Table Grading Severity Adult Pediatric Adverse Events , Version 1.0 December 2004 : Grade 1 high AST ALT Grade 1 high creatinine Grade 2 high hemoglobin Grade 1 high platelet ( Note : otherwise eligible participant exclusionary test may retested screen process ) . Any condition , opinion Investigator , would preclude provision consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Anti-HIV agent</keyword>
	<keyword>HIV-1</keyword>
</DOC>